Literature DB >> 23752604

Serum IL-10 and IL-12 levels reflect the response to chemotherapy but are influenced by G-CSF therapy and sepsis in children with soft tissue sarcomas.

Ewa Bien1, Malgorzata Krawczyk, Ewa Izycka-Swieszewska, Piotr Trzonkowski, Bernarda Kazanowska, Elzbieta Adamkiewicz-Drozynska, Anna Balcerska.   

Abstract

INTRODUCTION: Pre-treatment serum IL-10/IL-12 balance has been recently found deregulated in childhood soft tissue sarcomas (STS). Its role in STS monitoring and assessment of response to therapy is unknown.
OBJECTIVE: To establish whether serum IL-10 and IL-12 levels and their reciprocal ratios reflect childhood STS course and actual activity and whether G-CSF therapy and central vein catheter (CVC)-related sepsis influence the interleukins levels.
MATERIALS AND METHODS: ELISA determinations of serum interleukins were performed before treatment, in remission without complications (CR), at relapse and after treatment in 59 STS patients and during G-CSF administration and CVC-related sepsis (in 18) and also in 30 healthy controls.
RESULTS: In CR IL-10 declined and IL-12 increased as compared to pretreatment levels; in relapse IL-10 rose and IL-12 decreased significantly as compared to levels in CR. Also rates of IL-10, IL-12, and IL-10/IL-12 ratios recently estimated by us as of prognostic significance reflected well the STS course. During G-CSF therapy and CVC-related sepsis, IL-10 increased and IL-12 decreased significantly from levels in CR without complications. IL-10 levels and rates of IL-10 ≥ 11 pg/ml in sepsis could falsely suggest relapse. However, IL-12 levels, rates of IL-12 ≤ 60 pg/ml and/or simultaneous determination of both interleukins differed significantly from levels at relapse.
CONCLUSION: Serial determinations of serum IL-10 and IL-12 reflected well the course of STS in children and enabled remission and relapse phases to be distinguished. To avoid G-CSF and sepsis influence, IL-12 and IL-10/IL-12 ratio and not IL-10 alone should be analysed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23752604     DOI: 10.5604/17322693.1051646

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  2 in total

1.  Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.

Authors:  Kelong Han; Thomas Peyret; Angelica Quartino; Nathalie H Gosselin; Sridharan Gururangan; Michela Casanova; Johannes H M Merks; Maura Massimino; Jacques Grill; Najat C Daw; Fariba Navid; Jin Jin; David E Allison
Journal:  Br J Clin Pharmacol       Date:  2015-12-10       Impact factor: 4.335

2.  The Effect of Clown Intervention on Self-Report and Biomarker Measures of Stress and Fatigue in Pediatric Osteosarcoma Inpatients: A Pilot Study.

Authors:  Luis C Lopes-Júnior; Gabriela Pereira-da-Silva; Denise S C Silveira; Luciana C Veronez; Jéssica C Santos; Jonas B Alonso; Regina A G Lima
Journal:  Integr Cancer Ther       Date:  2018-06-14       Impact factor: 3.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.